Construction of CD4-based chimeric molecules by chemical cross-linking

Area of Science:

• Bioconjugation Chemistry
• Immunology
• Drug Development

Background:

• Soluble CD4 (sT4) is a key target for HIV therapeutics.
• Existing methods for conjugating sT4 to carriers can be inefficient or lack stability.
• Novel strategies are needed to create stable, functional sT4 conjugates for therapeutic applications.

Purpose of the Study:

• To describe a simple, efficient chemical method for conjugating soluble human CD4 (sT4) to diverse carriers.
• To demonstrate the stability and retained functionality of sT4 conjugates.
• To explore the potential of this method for developing CD4-based anti-HIV therapeutics.

Main Methods:

• Chemical coupling of sT4 to carriers using the bifunctional reagent sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC).
• Introduction of thiol (SH) groups to carriers using 2-iminothiolane when necessary.
• Characterization of sT4 conjugates, including binding assays with gp120 and anti-CD4 antibodies, and assessment of stability.

Main Results:

• The sulfo-SMCC method efficiently created stable thioether bonds between sT4 and carriers (human serum albumin, monoclonal antibody, red blood cells).
• sT4 reactivity for gp120 and anti-CD4 antibodies was preserved in all conjugates.
• sT4-Ig conjugates retained Ig binding specificity, and sT4-RBC conjugates showed high efficiency and homogeneity.

Conclusions:

• The described chemical coupling method is simple, fast, and efficient for creating stable sT4 conjugates.
• This approach allows for the construction of chimeric molecules not achievable through genetic engineering.
• The method holds significant potential for the rapid development and screening of CD4-based anti-HIV drugs.